Trial tests if powerful new drug trio can control lymphoma, then let patients stop treatment
NCT ID NCT05951959
Summary
This study is testing a combination of three targeted drugs (acalabrutinib, venetoclax, and rituximab) for adults newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goal is to see if this chemotherapy-free approach can put the cancer into a very deep remission where no cancer cells can be detected. For patients who achieve this deep remission, the study will then test whether they can safely stop all treatment and be monitored, with the option to restart a drug if the cancer returns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Stony Brook, New York, 11794, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Kogarah, NSW 2217, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Sydney, 2109, Australia
-
Research Site
Porto Alegre, 90035-003, Brazil
-
Research Site
Rio de Janeiro, 22061-080, Brazil
-
Research Site
São Paulo, 01401-002, Brazil
-
Research Site
São Paulo, 05403-010, Brazil
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
Research Site
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Research Site
Barrie, Ontario, L4M 6M2, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Gdynia, 81-519, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Madrid, 28041, Spain
-
Research Site
Birmingham, B9 5SS, United Kingdom
-
Research Site
Gloucester, GL1 3NN, United Kingdom
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
Norwich, NR4 7UY, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Plymouth, PL68BQ, United Kingdom
Conditions
Explore the condition pages connected to this study.